Drug Discovery

TCR Therapeutics

Identifying and Advancing Therapeutic TCRs

Our T-cell receptor (TCR) discovery approach allows us to identify naturally-occurring, potent TCRs for clinical development and commercialization with partners or on our own. To date, we have identified and characterized more than 8,000 unique antigen-specific TCRs against 600 clinically relevant targets. This represents a massive library of therapeutic grade TCRs.

Differentiators of Adaptive’s Approach

Versatility

  • Use blood samples
  • Target any antigen (the entire proteome)
  • Class I and II HLAs

Safety

  • Naturally-occurring, fully human TCRs
  • TCRs that have undergone thymic selection

High-throughput, high sensitivity

  • Test 1000s of antigens in a single screen
  • Identify ultra-low frequency TCRs
  • Accurate pairing of 100s of 1000s of TCR alpha/beta chains

Selection of best clinical candidates

  • Query entire TCR repertoire
  • Evaluate well-characterized, naturally-optimized, cytotoxic TCRs
  • Flexibility for multi-targeting by using combinations of potent TCRs